Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 10/20 | 0.56 |
| ▸ | CA2 | P00918 | 10/20 | 0.56 |
| ▸ | CA9 | Q16790 | 7/20 | 0.56 |
| ▸ | CA12 | O43570 | 6/20 | 0.56 |
| ▸ | CA5A | P35218 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.51 |
| ▸ | CA4 | P22748 | 3/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29581383 | 1.00 | HTR6 (0.60) | HTR6CA1CA2CA9CA12 | |
| Hydrochloric Acid SCHEMBL29713481 | 0.98 | HTR6 (0.58) | HTR6CA1CA2CA9CA12 | |
| Hydrochloric Acid SCHEMBL4910433 | 0.98 | HTR6 (0.58) | HTR6CA1CA2CA9CA12 | |
| SCHEMBL8395849 | 0.92 | CA1 (0.54) | HTR6CA1CA2CA9CA12 | |
| SCHEMBL10864060 | 0.88 | HTR6 (0.49) | HTR6CA1CA2CA9CA12 | |
| SCHEMBL32667731 | 0.86 | HTR6 (0.46) | HTR6CA1CA2CA9CA12 | |
| SCHEMBL7487045 | 0.84 | CA1 (0.46) | HTR6CA1CA2CA9CA12 | |
| SCHEMBL3380244 | 0.84 | HTR6 (0.49) | HTR6CA1CA2CA9CA12 | |
| SCHEMBL28890398 | 0.83 | HTR6 (0.47) | HTR6CA1CA2CA9CA12 | |
| SCHEMBL10529086 | 0.82 | CA2 (0.54) | CA1CA2CA9CA12CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 809 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | Alesta Therapeutics BV (NL) | 2026-05-19 | — | — | US | claimed |
| US-12331026-B2 | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | claimed |
| CN-119836416-A | KAT6 targeting compounds with ubiquitin ligase binding moiety | 普莱鲁德疗法有限公司 | 2025-04-15 | — | — | CN | claimed |
| CN-119119940-A | Isocyanate adhesive composition, formaldehyde-free artificial board and preparation method thereof | 万华化学（北京）有限公司 | 2024-12-13 | — | — | CN | claimed |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-12-05 | — | — | US | claimed |
| US-11987566-B2 | Nerve damage preventing and nerve protecting compounds, preparation method thereof, pharmaceutical composition thereof, and their use | GENHEALTH PHARMA CO., LTD. (TW) | 2024-05-21 | — | — | US | claimed |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-09-28 | — | — | US | claimed |
| EP-4230622-A1 | NERVE DAMAGE PREVENTING AND NERVE PROTECTING COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND THEIR USE | Genhealth Pharma Co., Ltd. (TW) | 2023-08-23 | — | — | EP | claimed |
| US-20230242501-A1 | NERVE DAMAGE PREVENTING AND NERVE PROTECTING COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND THEIR USE | GENHEALTH PHARMA CO., LTD. (TW) | 2023-08-03 | — | — | US | claimed |
| CN-116143746-A | Compound for preventing nerve injury and protecting nerve, its preparation method, medicinal products and application | 健裕生技股份有限公司 | 2023-05-23 | — | — | CN | claimed |
| EP-1644008-A2 | CONTINUOUS DOSING REGIMEN WITH ABT-751 | Abbott Laboratories (US) | 2006-04-12 | — | — | EP | claimed |
| WO-2005117903-A1 | TREATMENT OF CANCER IN PEDIATRIC PATIENTS | ABBOTT LABORATORIES (US) | 2005-12-15 | — | — | WO | claimed |
| WO-2004105794-A2 | CONTINUOUS DOSING REGIMEN WITH ABT-751 | ABBOTT LABORATORIES (US) | 2004-12-09 | — | — | WO | claimed |
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | UBE INDUSTRIES, LTD. (JP) | 2003-11-20 | — | — | US | claimed |
| EP-1254897-A1 | TRICYCLIC COMPOUNDS | Ube Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | claimed |
| JP-2000515505-A | — | — | 2000-11-21 | — | — | JP | claimed |
| EP-0917528-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | Astra Aktiebolag (SE) | 1999-05-26 | — | — | EP | claimed |
| WO-1998001422-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRA AKTIEBOLAG (SE) | 1998-01-15 | — | — | WO | claimed |
| EP-0132230-B1 | PROCESS FOR THE PREPARATION OF SULFONYL UREA | CIBA-GEIGY AG (CH) | 1988-10-05 | — | — | EP | claimed |
| EP-0132230-A2 | Process for the preparation of sulfonyl urea | CIBA-GEIGY AG (CH) | 1985-01-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | NR3C1, GCN1, EIF2AK4 | HTR6 443/4885CA1 3553/4885CA2 1341/4885 |
| US-11987566-B2 | Nerve damage preventing and nerve protecting compounds, preparation method thereof, pharmaceutical composition thereof, and their use | NGF, GAP43, ACHE | HTR6 3904/4885CA1 3758/4885CA2 3674/4885 |
| US-20230242501-A1 | NERVE DAMAGE PREVENTING AND NERVE PROTECTING COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND THEIR USE | NGF, GAP43, ACHE | HTR6 3904/4885CA1 3758/4885CA2 3674/4885 |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | CDK2, CCNK, CCNI | HTR6 3455/4885CA1 3540/4885CA2 2801/4885 |
| US-12331026-B2 | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors | CDK2, CCNK, CCNI | HTR6 3455/4885CA1 3540/4885CA2 2801/4885 |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | TP53, TP53BP1, MDM2 | HTR6 3835/4885CA1 2782/4885CA2 3601/4885 |
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | CYSLTR2, CYSLTR1, LTC4S | HTR6 1747/4885CA1 2057/4885CA2 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.